Rémy Duléry, MD, PhD, Saint-Antoine Hospital, Paris, France, outlines the main side effects associated with post-transplant cyclophosphamide (PTCy) as prophylaxis for graft-versus-host disease (GvHD) following haploidentical transplant (haplo-transplant) and discusses whether dose reduction of PTCy is a feasible approach for patients. As dose-reduction maintains the efficacy of GvHD prophylaxis while conferring additional clinical benefit, it may make haplo-transplant available to unfit patients who would not otherwise be eligible for this treatment option. Dr Duléry also highlights the questions that he believes future randomized control trials should aim to answer in this area, such as defining the optimal dose of PTCy and the optimal combination of immunosuppressive drugs that should be used when the PTCy dose is reduced. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
